Effect of fenofibrate on uric acid metabolism and urate transporter 1

Internal Medicine

Volumn 49, Issue 2, 2010, Pages 89-94

  Uetake, Daijiro ^a   Ohno, Iwao ^a   Ichida, Kimiyoshi ^b   Yamaguchi, Yuichiro ^a   Saikawa, Hajime ^a   Endou, Hitoshi ^c   Hosoya, Tatsuo ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES   (Japan)

^c KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fenofibrate; Fenofibric acid; URAT1; Uric acid

Indexed keywords

BENZBROMARONE; FENOFIBRATE; FENOFIBRIC ACID; HYPOXANTHINE; LOSARTAN; ORGANIC ANION TRANSPORTER; UNCLASSIFIED DRUG; URATE TRANSPORTER 1; URIC ACID; XANTHINE;

ADULT; ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG ACTIVITY; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HYPERURICEMIA; IC 50; IN VITRO STUDY; MALE; NORMAL HUMAN; SINGLE DRUG DOSE; URIC ACID BLOOD LEVEL; URIC ACID URINE LEVEL; URINARY EXCRETION;

ADULT; CELL LINE; HUMANS; MALE; ORGANIC ANION TRANSPORTERS; ORGANIC CATION TRANSPORT PROTEINS; PROCETOFEN; URIC ACID;

EID: 75749156653     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.2597     Document Type: Article

References (21)

1. Breckenridge A. Hypertension and hyperuricemia. Lancet 1: 15-18, 1966.
2. Berkowitz D. Blood lipid and uric acid interrelationships. JAMA 190: 856-858, 1964.
3. Jiao S, Kameda K, Matsuzawa Y, Tarui S. Hyperlipoproteinaemia in primary gout: hyperlipoproteinaemic phenotype and influence of alcohol intake and obesity in Japan. Ann Rheum Dis 45: 308-313, 1986.
4. Alderman MH, Cohen H, Madhavan S, Kivlighn S. Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 34: 144-150, 1999.
5. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 36: 1072-1078, 2000.
6. Hoieggen A, Alderman MH, Kjeldsen SE, et al; LIFE Study Group. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 65: 1041-1049, 2004.
7. Desager JP, Hulhoven R, Harvengt C. Uricosuric effect of fenofibrate in healthy volunteers. J Clin Pharmacol 20: 560-564, 1980.
8. Harvengt C, Heller F, Desager JP. Hypolipidemic and hypouricemic action of fenofibrate in various types of hyperlipoproteinemias. Artery 7: 73-82, 1980.
9. Enomoto A, Kimura H, Chairoungdua A, et al. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 417: 447-452, 2002.
10. Abe S, Ono K, Mogi M, Hayashi T. High-performance liquid chromatographic method for the determination of fenofibric acid and reduced fenofibric acid in human blood, plasma and urine. Yakugaku Zasshi 118: 447-455, 1998 (in Japanese, Abstract in English).
11. 14C-fenofibrate in human volunteers. Drug Metab Dispos 18: 115-120, 1990.
12. Staels B, Vu-Dac N, Kosykh VA, et al. Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates. J Clin Invest 95: 705-712, 1995.
13. Schoonjans K, Staels B, Auwerx J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res 37: 907-925, 1996.
14. Gebel T, Arand M, Oesch F. Induction of the peroxisome proliferator activated receptor by fenofibrate in rat liver. FEBS Lett 309: 37-40, 1992.
15. Sica DA, Schoolwerth AC. Renal handling of organic anions and cations: Excretion of uric acid. In: The Kidney. 6th ed. Brenner BM, Rector FC Jr, Eds. Saunders Co., New York, 2000: 680-700.
16. Levinson DJ, Sorensen LB. Renal handling of uric acid in normal and gouty subject. evidence for a 4-component system. Ann Rheum Dis 39: 173-179, 1980.
17. Nakashima M, Uematsu T, Kosuge K, Kanamaru M. Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 42: 333-335, 1992.
18. Puig JG, Mateos F, Buño A, Ortega R, Rodriguez F, Dal-Ré R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 17: 1033-1039, 1999.
19. Nakamura T, Nakaya N. Pharmacokinetics of GRS-001 in the elderly. Clin Eval 23: 59-72, 1995 (in Japanese).
20. Hamada T, Hisatome I, Kinugasa Y, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 41: 793-797, 2002.
21. Anzai N, Ichida K, Jutabha P, et al. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 283: 26834-26838, 2008.